Table 2.
Selected studies of neoadjuvant chemoradiation.
| Study Institution | Number of patients | Total dose of XRT (Gy) | Chemo-therapy (mg/m 2 ) | Median OS (months) | 1(2,4,5)-year-OS-rate (%) | Rate local recurrence (%) | Rate of resectability (%) | Rate of clear resections |
| Hoffman et al. 1998 [39, 40] multi-centric | 53 | 50.4 | 5-FU/MMC | 9.7 all pts 15.7 res |
2y: 27 res | 24/53 (26 %) 3/24 (13%) res |
24/53 (45%) | n.a |
| Snady et al. 2000 [29] Mount Sinai | 159 68* (20 res§) 91 adj |
54 + 14 Gy | 5-FU/cDDP/Streptozotocin | 23.6* (32 res) 14.0 |
1 y: 86*(89)vs.64 2y: 58*(60) vs.32 3y: 27*(40)vs.17 |
n.a. | 20/68 (29%) - |
95% neo 84% adj |
| Breslin et al. 2001 [20] MDACC | 132 | 45 or 50.4 Gy or 10 × 3 Gy ± IORT |
5-FU, or Tax or Gem | 21 |
1y: 75 2y: 40 5y: 23 |
8/132 (6%) | - | 88% |
| Sasson AR et al.2003 [28] FCCC | 116 61 neo 55 adj |
50.4 | 5-FU/MMC or Gem | all 18 neo 23 adj 16 |
n.a. | n.a. | - | 39% n.a. n.a. |
| White et al. 2005 [21] Duke | 193 i.p.r.:102 i.l.f.: 91 |
45 + 5.4 Gy | 5-FU or Gem | 23 39 i.p.r. 20 i.l.f. |
3y: 37 res 5y: 27 res |
n.a. | 70/193 (36%) 54/102 (53%) 16/91 (18%) |
73% n.a. n.a. |
Abbreviations: 5-FU = 5-fluorouracil; adj = adjuvant therapy; cDDP = cisplatin; FCCC = Fox Chase Cancer Center, Philadelphia, PA; Gem = gemcitabine; Gy = Dose in Gray; i.p.r = initially potentially resectable; i.l.f. = initially locally advanced, MDACC = M.D. Anderson Cancer Center Houston, TX; MMC = mitomycin C; n.a. = not available; neo = neoadjuvant; OS = overall survival; res = resected patients, RT = radiotherapy; Tax = paclitaxel; vs. = versus. *initially unresectable patients ± resection after chemoradiation; § this study indicates overall survival as explained: (1) patients with chemoradiation (2) numbers in brackets: patients with chemoradiation and resection (3) right to 'vs.': patients after primary resection; § numbers in brackets in this row give results of the 20/68 resected patients with RCT.